Biological markers (i.e. biomarkers) are necessary to translate mechanistic studies in rodents to human settings, and for monitoring risk and progression of disease in live subjects. Examples of studies performed in our group include testing the potential of gene expression to predict non-remission in depression prior to antidepressant treatment initiation, of proteomic, structural and imaging data to predict cognitive impairment in late-life depression, and of integrated genetic scores to predict higher risk for having depression in later life.
– Belzeaux R, Lin CW, Ding Y, Bergon A, Ibrahim EC, Turecki G, Tseng G, Sibille E. Predisposition to treatment response in major depressive episode: A peripheral blood gene coexpression network analysis. J Psychiatr Res. 2016 Oct;81:119-26. PubMed PMID: 27438688.
– Diniz BS, Sibille E, Ding Y, Tseng G, Aizenstein HJ, Lotrich F, Becker JT, Lopez OL, Lotze MT, Klunk WE, Reynolds CF, Butters MA. Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry. 2015 May;20(5):594-601. PubMed PMID: 25092249; PubMed Central PMCID: PMC4494754.
– Guilloux JP, Bassi S, Ding Y, Walsh C, Turecki G, Tseng G, Cyranowski JM, Sibille E. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology. 2015 Feb;40(3):701-10. PubMed PMID: 25176167; PubMed Central PMCID: PMC4289958.
– Diniz BS, Reynolds CF 3rd, Begley A, Dew MA, Anderson SJ, Lotrich F, Erickson KI, Lopez O, Aizenstein H, Sibille EL, Butters MA. Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study. J Psychiatr Res. 2014 Feb;49:96-101. PubMed PMID: 24290367; PubMed Central PMCID: PMC3921964.